🇺🇸 FDA
Pipeline program

OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab intravenous

IB 2019-03

Phase 2 small_molecule active

Quick answer

OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab intravenous for Adult participants with advanced unresectable or metastatic soft-tissue sarcoma. is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
Adult participants with advanced unresectable or metastatic soft-tissue sarcoma.
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials